These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24363530)

  • 41. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
    Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
    Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.
    Ye XG; Su QM
    World J Gastroenterol; 2013 Oct; 19(39):6665-78. PubMed ID: 24151397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
    Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
    Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study.
    Yang T; Lu JH; Zhai J; Lin C; Yang GS; Zhao RH; Shen F; Wu MC
    Eur J Surg Oncol; 2012 Aug; 38(8):683-91. PubMed ID: 22621971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Timing and selection of antiviral therapy with nucleos(t)ide analogues for prevention of hepatitis B virus-related HCC].
    Han C; Lai PP; Dou XG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):827-830. PubMed ID: 31941235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk.
    Ren P; Cao Z; Mo R; Liu Y; Chen L; Li Z; Zhou T; Lu J; Liu Y; Guo Q; Chen R; Zhou H; Xiang X; Cai W; Wang H; Bao S; Xu Y; Gui H; Xie Q
    Expert Opin Biol Ther; 2018 Oct; 18(10):1085-1094. PubMed ID: 30182763
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
    Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
    Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
    Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
    Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
    J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
    Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
    Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.
    Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH
    Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma.
    Huang L; Li J; Lau WY; Yan J; Zhou F; Liu C; Zhang X; Shen J; Wu M; Yan Y
    J Gastroenterol Hepatol; 2012 Jan; 27(1):158-64. PubMed ID: 21871026
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy.
    Tawada A; Kanda T; Imazeki F; Yokosuka O
    Hepatol Int; 2016 Jul; 10(4):574-93. PubMed ID: 27026375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
    Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
    Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis.
    Gao X; Yang HI; Trinh H; Jeong D; Li J; Zhang J; Le A; Hoang J; Nguyen P; Henry L; Nguyen MH
    Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1207-1211. PubMed ID: 32129773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
    Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.